PL339740A1 - Kay - a novel immune system protein - Google Patents
Kay - a novel immune system proteinInfo
- Publication number
- PL339740A1 PL339740A1 PL98339740A PL33974098A PL339740A1 PL 339740 A1 PL339740 A1 PL 339740A1 PL 98339740 A PL98339740 A PL 98339740A PL 33974098 A PL33974098 A PL 33974098A PL 339740 A1 PL339740 A1 PL 339740A1
- Authority
- PL
- Poland
- Prior art keywords
- kay
- immune system
- system protein
- novel immune
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5878697P | 1997-09-12 | 1997-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL339740A1 true PL339740A1 (en) | 2001-01-02 |
Family
ID=22018915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98339740A PL339740A1 (en) | 1997-09-12 | 1998-09-11 | Kay - a novel immune system protein |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1012270A2 (en) |
| JP (1) | JP2001515711A (en) |
| KR (1) | KR20010023892A (en) |
| CN (1) | CN1269832A (en) |
| AU (1) | AU9315298A (en) |
| BR (1) | BR9812433A (en) |
| CA (1) | CA2303424A1 (en) |
| EA (1) | EA200000311A1 (en) |
| EE (1) | EE200000148A (en) |
| HU (1) | HUP0004034A3 (en) |
| IL (1) | IL134480A0 (en) |
| IS (1) | IS5375A (en) |
| NO (1) | NO20001240L (en) |
| PL (1) | PL339740A1 (en) |
| SK (1) | SK3532000A3 (en) |
| TR (1) | TR200000654T2 (en) |
| WO (1) | WO1999012964A2 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| JP2002503444A (en) * | 1997-11-26 | 2002-02-05 | イーライ・リリー・アンド・カンパニー | Ligand family genes |
| WO1999033980A2 (en) * | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
| US6297367B1 (en) * | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| PL198934B1 (en) | 1999-01-25 | 2008-08-29 | Apoxis Sa | Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses |
| US6475986B1 (en) | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
| NZ513290A (en) * | 1999-02-23 | 2004-05-28 | Human Genome Sciences Inc | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
| US6475987B1 (en) | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
| DK1210425T4 (en) * | 1999-08-17 | 2015-08-10 | Apotech R & D Sa | BAFF receptor (BCMA), an immunoregulatory agent |
| UA74798C2 (en) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
| CA2399387C (en) | 2000-02-11 | 2015-11-03 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
| DK1255558T3 (en) | 2000-02-16 | 2006-10-23 | Genentech Inc | Anti-April antibodies and hybridoma cells |
| US20020086018A1 (en) | 2000-05-12 | 2002-07-04 | Theill Lars Eyde | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| PT2275449T (en) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
| CA2419661A1 (en) * | 2000-08-15 | 2002-03-07 | Guo-Liang Yu | Neutrokine-alpha and neutrokine-alpha splice variant |
| US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
| UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
| ES2527471T3 (en) | 2001-05-11 | 2015-01-26 | Amgen Inc. | Peptides and related molecules that bind to TALL-1 |
| AR035119A1 (en) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
| US7700317B2 (en) | 2003-03-28 | 2010-04-20 | Biogen Idec Ma Inc. | Truncated baff receptors |
| KR20060027801A (en) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Combination therapy for b cell disorders |
| MXPA06004301A (en) | 2003-10-20 | 2006-06-05 | Biogen Idec Inc | Therapeutic regimens for baff antagonists. |
| EP1709072A1 (en) * | 2004-01-29 | 2006-10-11 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| WO2006041680A2 (en) | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
| WO2006044582A2 (en) | 2004-10-13 | 2006-04-27 | The Washington University | Use of baff to treat sepsis |
| CA2590461A1 (en) | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | Bcma polypeptides and uses thereof |
| EP1922080A2 (en) | 2005-08-09 | 2008-05-21 | ZymoGenetics, Inc. | Methods for treating b-cell malignancies using taci-ig fusion molecule |
| CA2618763A1 (en) | 2005-08-09 | 2007-02-15 | Zymogenetics, Inc. | Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| CN101489573B (en) | 2006-05-15 | 2013-05-22 | 阿雷斯贸易股份有限公司 | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP3211094A3 (en) | 2009-09-03 | 2017-11-01 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| KR20140022815A (en) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | Biological markers and methods for predicting response to b-cell antagonists |
| JP6636803B2 (en) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Method for selection of antibodies to BCMA |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US10138251B2 (en) | 2014-04-11 | 2018-11-27 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994018325A1 (en) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
| AU6166396A (en) * | 1995-06-07 | 1996-12-30 | Biogen, Inc. | Complexes of modified lymphotoxins as pharmaceutical prepara tions |
| EP2230307A1 (en) * | 1996-10-25 | 2010-09-22 | Human Genome Sciences, Inc. | Neutrokine alpha |
| AU5705898A (en) * | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| CA2232743A1 (en) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
-
1998
- 1998-09-11 WO PCT/US1998/019037 patent/WO1999012964A2/en not_active Application Discontinuation
- 1998-09-11 HU HU0004034A patent/HUP0004034A3/en unknown
- 1998-09-11 JP JP2000510769A patent/JP2001515711A/en not_active Withdrawn
- 1998-09-11 AU AU93152/98A patent/AU9315298A/en not_active Abandoned
- 1998-09-11 EE EEP200000148A patent/EE200000148A/en unknown
- 1998-09-11 BR BR9812433-1A patent/BR9812433A/en not_active IP Right Cessation
- 1998-09-11 IL IL13448098A patent/IL134480A0/en unknown
- 1998-09-11 TR TR2000/00654T patent/TR200000654T2/en unknown
- 1998-09-11 KR KR1020007002576A patent/KR20010023892A/en not_active Application Discontinuation
- 1998-09-11 EA EA200000311A patent/EA200000311A1/en unknown
- 1998-09-11 SK SK353-2000A patent/SK3532000A3/en unknown
- 1998-09-11 CA CA002303424A patent/CA2303424A1/en not_active Abandoned
- 1998-09-11 PL PL98339740A patent/PL339740A1/en not_active Application Discontinuation
- 1998-09-11 CN CN98809023A patent/CN1269832A/en active Pending
- 1998-09-11 EP EP98946052A patent/EP1012270A2/en not_active Withdrawn
-
2000
- 2000-02-11 IS IS5375A patent/IS5375A/en unknown
- 2000-03-09 NO NO20001240A patent/NO20001240L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0004034A2 (en) | 2001-03-28 |
| NO20001240L (en) | 2000-05-10 |
| NO20001240D0 (en) | 2000-03-09 |
| CN1269832A (en) | 2000-10-11 |
| AU9315298A (en) | 1999-03-29 |
| TR200000654T2 (en) | 2000-07-21 |
| WO1999012964A2 (en) | 1999-03-18 |
| WO1999012964A3 (en) | 1999-05-27 |
| BR9812433A (en) | 2000-09-26 |
| KR20010023892A (en) | 2001-03-26 |
| SK3532000A3 (en) | 2001-12-03 |
| CA2303424A1 (en) | 1999-03-18 |
| IL134480A0 (en) | 2001-04-30 |
| IS5375A (en) | 2000-02-11 |
| EA200000311A1 (en) | 2000-10-30 |
| EE200000148A (en) | 2001-02-15 |
| HUP0004034A3 (en) | 2002-08-28 |
| JP2001515711A (en) | 2001-09-25 |
| EP1012270A2 (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0004034A3 (en) | Kay - a novel immune system protein | |
| IL121454A0 (en) | Internet-telephone interface system | |
| ZA9710338B (en) | Proteins | |
| GB9510830D0 (en) | Proteins | |
| GB9703681D0 (en) | Protein complemention | |
| GB9719879D0 (en) | Protein | |
| EP1018551A4 (en) | Megsin protein | |
| ZA984322B (en) | Sucrose-binding proteins | |
| GB9715064D0 (en) | Protein expression | |
| GB9720784D0 (en) | Protein | |
| GB9519865D0 (en) | Protein | |
| GB9622436D0 (en) | Protein | |
| EP0915100A4 (en) | Novel protein | |
| GB9722110D0 (en) | Conveyor system | |
| ZA971900B (en) | Modified proteins | |
| GB9706119D0 (en) | Novel protein | |
| GB9704252D0 (en) | Novel protein | |
| GB9714075D0 (en) | Novel protein | |
| GB9703850D0 (en) | Novel protein | |
| GB9703827D0 (en) | Novel protein | |
| GB9615810D0 (en) | Immune system invigorator | |
| GB9703103D0 (en) | Protein | |
| GB9719670D0 (en) | Protein | |
| GB9720785D0 (en) | Protein | |
| GB9722727D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |